Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

IL-27R alpha/WSX-1/TCCR Antibody (34N4G11), Allophycocyanin/Cy7, Novus Biologicals™
SDP

Mouse Monoclonal Antibody

Supplier:  Novus Biologicals NBP219015APCCY7

Catalog No. N219015APC7


Only null left
Add to Cart

Description

Description

IL-27R alpha/WSX-1/TCCR Monoclonal specifically detects IL-27R alpha/WSX-1/TCCR in Human samples. It is validated for Flow Cytometry, Flow (Cell Surface).
Specifications

Specifications

IL-27R alpha/WSX-1/TCCR
Monoclonal
APC-Cyanine7
PBS with 0.05% Sodium Azide
IL27RA
A portion of amino acids 200-250 of human IL-27R (WSX-1) was used as the immunogen for this antibody.
0.1 mL
Primary
IL-27R (WSX-1) is 65-70 kDa protein and is highly expressed in lymphoid tissues such as spleen, lymph nodes and peripheral blood leukocytes including CD4+ and CD8+ T cells, monocytes, DCs and NK cells
Store at 4°C in the dark. Do not freeze.
Flow Cytometry
34N4G11
Flow Cytometry, Flow (Cell Surface)
class I cytokine receptor, CRL1IL-27R, Cytokine receptor-like 1, IL27R, IL-27RA, IL-27R-alpha, interleukin 27 receptor, alpha, interleukin-27 receptor subunit alpha, TCCRIL-27 receptor subunit alpha, T-cell cytokine receptor type 1, Type I T-cell cytokine receptor, WSX-1, WSX1IL-27R subunit alpha, zcytor1
Mouse
Protein G purified
Apoptosis, Cytokine Research
9466.0
Human
IgG2b κ
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.